Histopathological and Immunohistochemical Prognostic Factors in High-Grade Non-Endometrioid Carcinomas of the Endometrium (HG-NECs): Is It Possible to Identify Subgroups at Increased Risk?
endometrial carcinoma
immunohistochemistry
prognosis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
26 Jun 2023
26 Jun 2023
Historique:
received:
02
05
2023
revised:
07
06
2023
accepted:
20
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Endometrial cancer is an emerging disease with an increase in prevalence of aggressive histotypes in recent years. In the present study, potential histopathological and immunohistochemical prognostic markers were investigated. Consecutive cases of high-grade non-endometrioid carcinoma (HG-NEC) of the endometrium were considered. Each surgical specimen was routinely processed; the most significant block was selected for immunohistochemistry and tested for ER, PR, ki67, p53, E-cadherin, β-catenin, Bcl-2 and cyclin D1. For each immunomarker, the percentage of positive tumor cells was evaluated (%) and dichotomized as low and high according to the distribution in the study population. Follow-up was collected for disease-free survival (DFS) and overall survival (OS). Thirty-three cases were eligible: 19 resulted in FIGO I-II; 14 resulted in FIGO III-IV. Twelve patients suffered a recurrent disease (mean follow-up 24.6 months); 8 patients died of the disease (mean follow-up 26.6 months). Women with recurrent disease demonstrated a significantly higher Bcl2% (35.84 ± 30.96% vs. 8.09 ± 11.56%; HG-NEC represents a heterogeneous group of endometrial aggressive neoplasms with a worrisome prognosis, often at an advanced stage at presentation. Bcl-2 and PR may represent promising markers to identify a subgroup of patients having an even worse prognosis requiring a careful and close follow-up.
Sections du résumé
Endometrial cancer is an emerging disease with an increase in prevalence of aggressive histotypes in recent years.
BACKGROUND
BACKGROUND
In the present study, potential histopathological and immunohistochemical prognostic markers were investigated. Consecutive cases of high-grade non-endometrioid carcinoma (HG-NEC) of the endometrium were considered.
METHODS
METHODS
Each surgical specimen was routinely processed; the most significant block was selected for immunohistochemistry and tested for ER, PR, ki67, p53, E-cadherin, β-catenin, Bcl-2 and cyclin D1. For each immunomarker, the percentage of positive tumor cells was evaluated (%) and dichotomized as low and high according to the distribution in the study population. Follow-up was collected for disease-free survival (DFS) and overall survival (OS). Thirty-three cases were eligible: 19 resulted in FIGO I-II; 14 resulted in FIGO III-IV. Twelve patients suffered a recurrent disease (mean follow-up 24.6 months); 8 patients died of the disease (mean follow-up 26.6 months).
RESULTS
RESULTS
Women with recurrent disease demonstrated a significantly higher Bcl2% (35.84 ± 30.96% vs. 8.09 ± 11.56%;
CONCLUSIONS
CONCLUSIONS
HG-NEC represents a heterogeneous group of endometrial aggressive neoplasms with a worrisome prognosis, often at an advanced stage at presentation. Bcl-2 and PR may represent promising markers to identify a subgroup of patients having an even worse prognosis requiring a careful and close follow-up.
Identifiants
pubmed: 37443564
pii: diagnostics13132171
doi: 10.3390/diagnostics13132171
pmc: PMC10341374
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Clin Exp Med. 2015 Oct 15;8(10):18689-96
pubmed: 26770483
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361
pubmed: 29045681
Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L830-8
pubmed: 12225960
Hum Pathol. 2004 Jun;35(6):649-62
pubmed: 15188130
Am J Surg Pathol. 2012 May;36(5):753-61
pubmed: 22498825
Cell Tissue Res. 2005 Oct;322(1):53-61
pubmed: 15947972
Clin Cancer Res. 2004 Aug 15;10(16):5546-53
pubmed: 15328195
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):197-203
pubmed: 12657124
Curr Opin Oncol. 2019 Sep;31(5):411-419
pubmed: 31261170
Obstet Gynecol. 2002 Dec;100(6):1290-5
pubmed: 12468176
Obstet Gynecol Int. 2010;2010:162363
pubmed: 20368795
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Pathol Oncol Res. 2008 Mar;14(1):23-30
pubmed: 18398703
Oncogene. 2003 Sep 4;22(38):6115-8
pubmed: 12955092
Indian J Pathol Microbiol. 2007 Oct;50(4):708-10
pubmed: 18306533
Gynecol Oncol. 1998 Nov;71(2):305-7
pubmed: 9826476
Am J Surg Pathol. 2007 Jul;31(7):979-87
pubmed: 17592263
Pathology. 2007 Feb;39(1):72-87
pubmed: 17365824
Cancer Res. 2001 Jun 1;61(11):4576-82
pubmed: 11389093
J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):221-9
pubmed: 18061438
J Pathol. 2020 Mar;250(3):336-345
pubmed: 31829441
Endocr J. 2007 Dec;54(5):667-79
pubmed: 17785917
Virchows Arch. 2004 Mar;444(3):213-23
pubmed: 14747944
Diagn Pathol. 2013 Aug 15;8:138
pubmed: 23947899
J Pathol. 1996 Nov;180(3):275-82
pubmed: 8958805
J Cell Biochem Suppl. 1995;23:151-9
pubmed: 8747390
Womens Health (Lond). 2014 May;10(3):277-88
pubmed: 24956294
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Virchows Arch. 2010 Jul;457(1):27-34
pubmed: 20552366
Acta Cytol. 1999 Nov-Dec;43(6):1039-44
pubmed: 10578976
Hum Pathol. 1996 Dec;27(12):1295-300
pubmed: 8958301
Mod Pathol. 2002 Oct;15(10):1032-7
pubmed: 12379748
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Eur J Cancer. 2007 Nov;43(16):2434-44
pubmed: 17911007
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Oncogene. 1998 Apr 30;16(17):2265-82
pubmed: 9619836
Hum Pathol. 2013 Jun;44(6):1047-54
pubmed: 23266443